US equities |
MU $934.27 ▲+0.00% INTC $92.07 ▲+0.00% SNDK $1,330.05 ▲+0.00% AMZN $243.79 ▲+0.00% GOOGL $283.82 ▲+0.00% NVDA $213.66 ▲+0.00% AAPL $348.91 ▲+0.00% AMD $566.42 ▲+0.00%
FinancialContent

Cytodyn Inc (OP:CYDY)

0.2250 UNCHANGED
Delayed Quote Updated: 3:59 PM EDT, Oct 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cytodyn Inc

< Previous 1 2 3 4 5 6 Next >
News headline image
CytoDyn Receives Clearance from Brazil’s FDA (ANVISA) to Commence a Pivotal Phase 3 Trial in Critically Ill COVID-19 Patients with IV Administration of Four Doses (700mg/week)
From CytoDyn Inc.
Via Business Wire
News headline image
CytoDyn’s Chairman, CMO, and Head of Business Development Dr. Scott A. Kelly to Present at the World Antiviral Congress 2021
From CytoDyn Inc.
Via Business Wire
News headline image
Group of CytoDyn Stockholders Announces Federal Court Dismisses Litigation Brought by Company
From Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via Business Wire
News headline image
CytoDyn Announces Resolution of Federal Litigation with Rosenbaum/Patterson Activist Group
From CytoDyn Inc.
Via Business Wire
News headline image
Bruce Patterson, M.D., Director Candidate for CytoDyn Board, Presents at International COVID Summit
From Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via Business Wire
News headline image
Glancy Prongay & Murray LLP Announces Investigation of CytoDyn Inc.
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
Group of CytoDyn Stockolders Responds to Misleading Company News Release
From Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via Business Wire
News headline image
CytoDyn Highlights Court Ordering Rosenbaum/Patterson Group to Comply With the Federal Securities Laws
From CytoDyn Inc.
Via Business Wire
Why Experts Believe Antibody Treatments Hold The Potential To Reduce Need For Hospitalization For COVID-19 Patients
Via FinancialNewsMedia
News headline image
Group of CytoDyn Stockholders Warns Stockholders of Board’s Continued Value Destruction and Failures
From Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via Business Wire
News headline image
The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
News headline image
Group of CytoDyn Stockholders Files Lawsuit to Force Company to Allow Stockholders to Vote for Alternative Director Nominees
From Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via Business Wire
News headline image
CytoDyn Urges Shareholders to Ignore Proxy Cards from Rosenbaum/Patterson Group
From CytoDyn
Via Business Wire
News headline image
Group of CytoDyn Stockholders Responds to Highly Misleading Company Release
From Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via Business Wire
News headline image
CytoDyn Provides Update on Rosenbaum/Patterson Group Litigation
From CytoDyn Inc.
Via Business Wire
News headline image
CytoDyn Files Lawsuit Against Rosenbaum/Patterson Activist Group for Misleading Shareholders and Waging an Unlawful Proxy Contest
From CytoDyn Inc.
Via Business Wire
News headline image
CytoDyn Receives Clearance from Brazil’s ANVISA to Commence Phase 3 Trial for Severe COVID-19 Patients
From CytoDyn Inc.
Via Business Wire
News headline image
CytoDyn Announces That Director Nominations by Rosenbaum/Patterson Activist Group Are Invalid
From CytoDyn Inc.
Via Business Wire
News headline image
CytoDyn Inc. (OTC: CYDY) Long Term Investor Notice: Investigation of Potential Wrongdoing ↗
San Diego, CA -- (SBWIRE) -- 07/28/2021 -- An investigation on behalf of current long term investors in CytoDyn Inc. (OTC: CYDY) shares over possible breaches of fiduciary duty by certain officers and... 
Via SBWire
Topics Lawsuit
News headline image
OTC Markets Hits Major Milestones in Mid-Year Along With Big Volume and Gaining Securities ↗
Photo by Kyrie Kim on Unsplash In a similar vein to 2020, the market’s volatility to start 2021 gave way to less volatility in the second quarter, and even less volatility... 
Via Benzinga
News headline image
Group of Cytodyn Stockholders Nominates Five Highly Qualified Director Candidates to Replace Board Responsible for Mismanagement and Value Destruction
From Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via Business Wire
News headline image
What's Behind This Wild-Card Coronavirus Stock? ↗
Failure is not an option for this small-cap biotech developing a COVID-19 treatment. 
Via The Motley Fool
News headline image
CytoDyn Plans To Send Topline Data From COVID-19 Trial Of Leronlimab To Regulators In India, Philippines ↗
After facing rebuke from FDA, CytoDyn Inc (OTC: CYDY) plans to submit the topline results of its CD12 Phase 3 trial of Vyrologix (leronlimab-PRO 140... 
Via Benzinga
News headline image
CytoDyn Stock Falls After FDA Rebukes Claims On COVID-19 Treatment ↗
The FDA has accused CytoDyn Inc (OTC: CYDY) of trying to pick and choose data from two failed studies of leronlimab in COVID-19 patients to claim the drug is... 
Via Benzinga
News headline image
DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against CytoDyn Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
The Daily Biotech Pulse: Spero Secures NIAID Funding, GlaxoSmithKline Releases COVID-19 Data, BioNTech Gets New CFO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 17) Alexion Pharmaceuticals, Inc... 
Via Benzinga
News headline image
DEADLINE MONDAY ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against CytoDyn Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against CytoDyn, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
News headline image
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against CytoDyn, Inc. (CYDY)
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
MONDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against CytoDyn Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
< Previous 1 2 3 4 5 6 Next >